Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma
暂无分享,去创建一个
M. Kudo | R. Kelley | D. Pinato | S. Kambhampati | Zhanjun Guo | Y. Yeo | M. Pinter | H. Tsai | F. Ji | B. Scheiner | Takaaki Tanaka | E. Xie | C. Fulgenzi | A. D’Alessio | Yih-Jyh Lin | Yue Zhang | Shuo Xu | Xin-Xing Tantai | Petros Fessas | Bridget P. Keenan | Z. Xing | Xu Gao | Wenjun Wang | Tiago de Castro | Hsin‐Yu Kuo | J. D. Yang | Arndt Vogel | Atsushi Hiraoka
[1] J. Bruix,et al. Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis , 2023, Hepatology.
[2] W. Hwang,et al. Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child‐Pugh B cirrhosis , 2022, Cancer medicine.
[3] M. Kudo,et al. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.
[4] H. Pan,et al. Efficacy and safety of PD‐1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study , 2022, Cancer medicine.
[5] Yi‐Hsiang Huang,et al. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma , 2022, Cancer Immunology, Immunotherapy.
[6] J. Trojan,et al. Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers , 2022, Cancers.
[7] M. Kudo,et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study , 2022, Hepatology.
[8] Qi Zhang,et al. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications , 2022, BMC cancer.
[9] Yingliang Wang,et al. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center , 2022, Frontiers in Oncology.
[10] A. Vogel,et al. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience , 2022, Therapeutic advances in medical oncology.
[11] Zhanjun Guo,et al. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors , 2021, Frontiers in Immunology.
[12] M. Morimoto,et al. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.
[13] S. Choo,et al. Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma , 2021, Liver Cancer.
[14] M. Kudo,et al. CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. , 2021, Journal of hepatology.
[15] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[16] J. Lee,et al. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves , 2020, BMC Medical Research Methodology.
[17] Jianming Xu,et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial , 2020, Clinical Cancer Research.
[18] L. Rimassa,et al. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study , 2020, Journal for ImmunoTherapy of Cancer.
[19] H. Lee,et al. Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study , 2020, Cancers.
[20] M. Kudo,et al. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements , 2020, Liver Cancer.
[21] Edward L. Giovannucci,et al. Global Burden of 5 Major Types Of Gastrointestinal Cancer. , 2020, Gastroenterology.
[22] Chiung‐Yu Chen,et al. Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma , 2020, Oncology Research and Treatment.
[23] S. Choo,et al. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian center. , 2020 .
[24] K. Lan,et al. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma , 2020, Cancers.
[25] S. Behr,et al. Nivolumab in patients with advanced hepatocellular carcinoma and Child‐Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series , 2019, Cancer.
[26] M. Kudo,et al. Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis. , 2019, Journal of hepatology.
[27] J. Trojan,et al. Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort , 2019, Alimentary pharmacology & therapeutics.
[28] J. Knox,et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. , 2018, European journal of cancer.
[29] J. Trojan,et al. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers , 2018, Journal of Cancer Research and Clinical Oncology.
[30] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[31] A. Gasbarrini,et al. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. , 2017, Journal of hepatology.
[32] J. Marrero,et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. , 2016, Journal of hepatology.
[33] T. Pawlik,et al. Hepatocellular carcinoma: From diagnosis to treatment. , 2016, Surgical oncology.
[34] M. Colombo,et al. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib , 2015, Hepatology.
[35] P. Hoff,et al. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. , 2015, Molecular and clinical oncology.
[36] Helena Carreira,et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2) , 2015, The Lancet.
[37] M. Álvarez-Mon,et al. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. , 2014, Journal of hepatology.
[38] R. Labianca,et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] S. Fan,et al. The use of single‐agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child‐Pugh B liver cirrhosis , 2012, Cancer.
[40] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[41] D. Amadori,et al. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. , 2011, Gastrointestinal cancer research : GCR.
[42] T. Greten,et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. , 2010, European journal of gastroenterology & hepatology.
[43] D. Moher,et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.
[44] Zhanjun Guo,et al. Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis , 2013, OncoTargets and therapy.